3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Interventions
Everolimus
6
lutetium Lu 177 dotatate
5
lanreotide
4
Octreotide
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
amino-acid, glucose, and electrolyte solution
3
Capecitabine
3
surufatinib
2
fluorodopa F 18
2
Introns
2
telotristat ethyl
1
copper dotatate CU-64
1
cabozantinib
1
X-Rays
1
Temozolomide
1
Sunitinib
1
Specimen Handling
1
Somatostatin
1
Serotonin
1
Salts
1
Phantoms, Imaging
1
Oxaliplatin
1
Magnetic Resonance Spectroscopy
1
Lutetium-177
1
Lutetium
1
Leucovorin
1
Interferon alpha-2
1
Immunoglobulin G
1
Ga(III)-DOTATOC
1
Furosemide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neuroendocrine Tumors
×
177Lu-octreotate
×
Clear all
NCT01860742
2016-04-05
CASTOR
Jules Bordet Institute
Phase 3
Withdrawn